EUVIMEDEUVIMED entdecken
Crossref

Kv1.3 Channel Blockade by Dalfampridine Attenuates NLRP3 Inflammasome‐Driven Demyelination via the NEK7/Ripk1/FADD Pathway, Matching the Efficacy of Broad P2X7 Antagonism by Suramin in EAE

Ahmed S Kamel, Heba Nasr Shalaby iD, Yasmin A M El-Said, Dalia A Nawwar

Drug Development Research · 2026

DOI: 10.1002/ddr.70318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Ahmed S Kamel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Suramin, Kv1.3 Potassium Channel, Purinergic P2X Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The loss of intracellular K + facilitated by different channels such as Panx1, TWIK2, or Kv1.3, is a danger signal that activates programmed cell death in oligodendrocytes via NLRP3 inflammasome and pyroptosis in multiple sclerosis (MS). ATP triggers P2X7 purinergic receptors, which coordinate TWIK‐2 and Panx‐1 channels. Given this hierarchical signaling architecture, the present study postulated that strategic Kv1.3 intervention using Dalfampridine (Dal) could mirror comprehensive P2X7 blockade with Suramin (Sur) in the experimental autoimmune encephalomyelitis (EAE) as MS animal model. EAE mice received either Dal (10 µg/mouse/day, oral for 2 weeks) or a single Sur injection (100 mg/kg, intraperitoneal). Both interventions demonstrated comparable efficacy in restoring motor function in open field and rotarod tests, preserving myelin integrity under Luxol fast blue stain, and attenuating neuroinflammatory infiltrates within spinal tissues. Molecular profiling confirmed EAE‐associated hyperactivation of the ATP‐P2X7R‐K⁺ efflux cascade. Sur exerted broad‐spectrum inhibition, suppressing ATP accumulation, P2X7R overexpression, and all three channels. Conversely, Dal specifically reduced Kv1.3 expression while leaving ATP levels, P2X7R, TWIK‐2, and pannexin‐1 unchanged. Remarkably, both compounds achieved equivalent disruption of NEK7/Ripk1/FADD/NLRP3 inflammasome complex and pyroptotic machinery, including pro‐caspas1 activation and subsequent gasdermin‐D cleavage. These findings suggest that Kv1.3 may serve as a contributory node where downstream channel modulation can deliver neuroprotection equivalent to the upstream pathway intervention. By modulating this potential checkpoint, Kv1.3‐targeted therapy may reduce collateral effects associated with pan‐purinergic blockade, offering a potential streamlined therapeutic corridor for demyelinating neuroinflammation with enhanced specificity and reduced systemic burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalomyelitis, Autoimmune, ExperimentalSuraminKv1.3 Potassium ChannelPurinergic P2X Receptor Antagonists4-AminopyridinePotassium Channel BlockersAnimalsNLR Family, Pyrin Domain-Containing 3 ProteinMiceInflammasomesFemaleMice, Inbred C57BLNIMA-Related KinasesReceptors, Purinergic P2X7Signal Transduction

Stichwörter der Autor:innen

NLRP3/inflammasome/NEK7/Ripk1/FADD/NLRP3dalfampridinemultiple sclerosispotassium efflux–facilitating channels (Kv1.3, TWIK2, or Panx1)purigenic P2X7 receptorsuramin

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesNlrp3 protein, mouseSuraminNek7 protein, mouseKv1.3 Potassium ChannelPurinergic P2X Receptor AntagonistsNIMA-Related KinasesReceptors, Purinergic P2X74-Aminopyridine

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Cairo, Egypt.

ORCID-Profile: Heba Nasr Shalaby

Zitieren

APA

Kamel, A. S., Shalaby, H. N., El-Said, Y. A. M., & Nawwar, D. A. (2026). Kv1.3 Channel Blockade by Dalfampridine Attenuates NLRP3 Inflammasome‐Driven Demyelination via the NEK7/Ripk1/FADD Pathway, Matching the Efficacy of Broad P2X7 Antagonism by Suramin in EAE. Drug Development Research. https://doi.org/10.1002/ddr.70318

Vancouver

Kamel AS, Shalaby HN, El-Said YAM, Nawwar DA. Kv1.3 Channel Blockade by Dalfampridine Attenuates NLRP3 Inflammasome‐Driven Demyelination via the NEK7/Ripk1/FADD Pathway, Matching the Efficacy of Broad P2X7 Antagonism by Suramin in EAE. Drug Development Research. 2026. doi:10.1002/ddr.70318

BibTeX
@article{Kamel2026,
  author = {Kamel, Ahmed S and Shalaby, Heba Nasr and El-Said, Yasmin A M and Nawwar, Dalia A},
  title = {Kv1.3 Channel Blockade by Dalfampridine Attenuates NLRP3 Inflammasome‐Driven Demyelination via the NEK7/Ripk1/FADD Pathway, Matching the Efficacy of Broad P2X7 Antagonism by Suramin in EAE},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70318}
}
Kostenlos starten →